CAM
ATXS

ClariVest Asset Management’s Astria Therapeutics ATXS Stock Holding History

ClariVest Asset Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$731K Hold
80,315
– – 0.07% 312
2024
Q2 		$731K Buy
+80,315
New +$784K 0.07% 312

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ClariVest Asset Management's ATXS Position: Q3 2024 in Review

ClariVest Asset Management held its Astria Therapeutics (ATXS) position steady in Q3 2024 at 80,315 shares worth $731K. The position accounts for 0.07% of the portfolio, ranked #312.

ClariVest Asset Management first reported a position in ATXS in Q2 2024 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold ATXS as of Q3 2024.

  • ClariVest Asset Management held 80,315 shares of Astria Therapeutics worth $731K as of Q3 2024.
  • ClariVest Asset Management left its Astria Therapeutics share count unchanged in Q3 2024.
  • Astria Therapeutics made up 0.07% of ClariVest Asset Management's portfolio in Q3 2024, its #312 holding.
  • ClariVest Asset Management first reported a position in Astria Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.